MA52783A - Modulation de la phagocytose cellulaire dépendant de l'anticorps - Google Patents

Modulation de la phagocytose cellulaire dépendant de l'anticorps

Info

Publication number
MA52783A
MA52783A MA052783A MA52783A MA52783A MA 52783 A MA52783 A MA 52783A MA 052783 A MA052783 A MA 052783A MA 52783 A MA52783 A MA 52783A MA 52783 A MA52783 A MA 52783A
Authority
MA
Morocco
Prior art keywords
antibody
modulation
dependent cellular
cellular phagocytosis
phagocytosis
Prior art date
Application number
MA052783A
Other languages
English (en)
Inventor
Scott T Kuhns
Junyan Shu
Qingchun Zhang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA52783A publication Critical patent/MA52783A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA052783A 2018-06-05 2019-06-05 Modulation de la phagocytose cellulaire dépendant de l'anticorps MA52783A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862680934P 2018-06-05 2018-06-05

Publications (1)

Publication Number Publication Date
MA52783A true MA52783A (fr) 2021-04-14

Family

ID=67314793

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052783A MA52783A (fr) 2018-06-05 2019-06-05 Modulation de la phagocytose cellulaire dépendant de l'anticorps

Country Status (8)

Country Link
US (1) US20210155710A1 (fr)
EP (1) EP3802610A1 (fr)
JP (2) JP7543144B2 (fr)
AU (1) AU2019282264A1 (fr)
CA (1) CA3099757A1 (fr)
MA (1) MA52783A (fr)
MX (1) MX2020013036A (fr)
WO (1) WO2019236739A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114144434A (zh) * 2019-05-06 2022-03-04 美国安进公司 调节抗体效应子功能
WO2021263221A1 (fr) * 2020-06-26 2021-12-30 Novather, Inc. Modulateur de liaison
JP2024537100A (ja) * 2021-10-05 2024-10-10 アムジエン・インコーポレーテツド Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2219361C (fr) 1995-04-27 2012-02-28 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
EP1972194A1 (fr) 1996-12-03 2008-09-24 Amgen Fremont Inc. Mammifères transgéniques disposant d'un loci ig comprenant plusieurs régions vh et vk et anticorps produits à partir de ceux-ci
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP4382170A3 (fr) 2009-12-06 2024-09-04 Bioverativ Therapeutics Inc. Polypeptides chimériques et hybrides de facteur viii-fc, et leurs procédés d'utilisation
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
WO2013114167A1 (fr) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Procédé d'obtention d'une composition de glycoforme
EP2809773B1 (fr) 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Procédé de modulation de man5 et/ou du taux d'afucosylation d'une composition de glycoprotéine
WO2013114164A1 (fr) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Procédé d'obtention d'une composition glycoprotéique ayant une concentration accrue d'afucosylation
KR20160003634A (ko) * 2013-02-13 2016-01-11 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항-her2 항체 및 이의 용도
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
WO2015128793A1 (fr) 2014-02-25 2015-09-03 Dr. Reddy’S Laboratories Limited Procédé pour modifier une composition de glycoprotéine afin d'obtenir une forte teneur en mannose et une galactosylation réduite
WO2015140700A1 (fr) 2014-03-19 2015-09-24 Dr. Reddy's Laboratories Limited Procédé de culture cellulaire
CA2969225C (fr) 2014-12-01 2023-08-22 Amgen Inc. Procede de manipulation du taux de contenu de glycane d'une glycoproteine
CN108431026B (zh) 2015-11-02 2023-02-17 豪夫迈·罗氏有限公司 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法
WO2017134667A1 (fr) 2016-02-02 2017-08-10 Insight Biopharmaceuticals Ltd. Procédés de génération d'anticorps

Also Published As

Publication number Publication date
CA3099757A1 (fr) 2019-12-12
JP2024161535A (ja) 2024-11-19
JP7543144B2 (ja) 2024-09-02
MX2020013036A (es) 2021-02-26
US20210155710A1 (en) 2021-05-27
WO2019236739A1 (fr) 2019-12-12
EP3802610A1 (fr) 2021-04-14
JP2021526014A (ja) 2021-09-30
AU2019282264A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
MX2020003125A (es) Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
EP3765522A4 (fr) Anticorps anti-claudine 18.2
IL282496A (en) Epcam antibodies, activatable antibodies, and immunoconjugates, and uses thereof
MA55818A (fr) Anticorps et immunoconjugués de fr-alpha biparatopique
SI3794042T1 (sl) Konjugat protitelesa anti-MUC1-exatecan in citotoksično sredstvo
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
EP3768854A4 (fr) Modulation de l'expression de hsd17b13
EP3741861A4 (fr) Expression régulée de l'il12 par le récepteur synnotch
EP3807318A4 (fr) Constructions d'anticorps multi-spécifiques
EP3607091A4 (fr) Régions constantes d'igm humaine modifiée pour la modulation de la fonction effectrice cytolytique dépendante du complément
SG11202011232VA (en) Anti-cd63 antibodies, conjugates, and uses thereof
EP3882349A4 (fr) Conjugué (anticorps anti-cdh6)-(dérivé de pyrrolobenzodiazépine)
EP3873381A4 (fr) Implants de surface articulaire dotés d'alvéoles
MA50369A (fr) Modulation de la réponse immunitaire à l'aide de conjugués anticorps-médicament
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
EP3840756A4 (fr) Synthèse améliorée de la 1,4-diazaspiro[5.5]undécan-3-one
IL276546A (en) Hydrophobic auristatin F compounds and their conjugates
EP3780979C0 (fr) Sous-vêtement pour homme
EP3885362A4 (fr) Conjugué d'anticorps
EP4042988A4 (fr) Coupe menstruelle
EP3849612A4 (fr) Variants d'anticorps anti-vih 10-1074
EP4010865A4 (fr) Intégration d'application mobile
EP3947466A4 (fr) Anticorps anti-hla-dq2.5
CA187857S (en) Men's undergarment
EP3700459C0 (fr) Ensemble d'implantation dentaire endo-osseux